Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5331450 | 0.82 | SHBG (0.52) | SHBGSTSNR3C1ALDH1A1HTR2B | |
| SCHEMBL6272318 | 0.73 | HSD17B1 (0.44) | SHBGGAA | |
| SCHEMBL9634786 | 0.73 | SHBG (0.31) | SHBG | |
| SCHEMBL4620745 | 0.69 | HSD17B1 (0.32) | SHBGDRD2HTR2AHTR2CHTR2B | |
| SCHEMBL7179498 | 0.68 | NR5A1 (0.34) | — | |
| SCHEMBL20952970 | 0.65 | MAPT (0.35) | KDM4EALDH1A1GAADRD2HTR2A | |
| SCHEMBL8052596 | 0.64 | SHBG (0.36) | SHBGSTS | |
| SCHEMBL8052597 | 0.64 | SHBG (0.36) | SHBGSTS | |
| SCHEMBL10619690 | 0.64 | SHBG (0.31) | SHBG | |
| SCHEMBL11096655 | 0.64 | SHBG (0.70) | SHBGSTSNR3C1ALDH1A1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156876-B2 | Modified, hydroxy-substituted aromatic structures having cytoprotective activity | WASHINGTON UNIVERSITY (US) | 2015-10-13 | — | — | US | disclosed |
| EP-1834959-B1 | Tert-butyl-substituted aromatic steroids having cytoprotective activity | UNIV WASHINGTON (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20110015165-A1 | MODIFIED, HYDROXY-SUBSTITUTED AROMATIC STRUCTURES HAVING CYTOPROTECTIVE ACTIVITY | WASHINGTON UNIVERSITY IN ST. LOUIS (US) | 2011-01-20 | — | — | US | disclosed |
| US-20080182829-A1 | 8Beta-Hydrocarbyl-Substituted Estratrienes As Selectively Active Estrogens | PETERS OLAF | 2008-07-31 | — | — | US | disclosed |
| US-7378404-B2 | 8β-hydrocarbyl-substituted estratrienes for use as selective estrogens | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-05-27 | — | — | US | disclosed |
| EP-1834959-A2 | Tert-butyl-substituted aromatic steroids having cytoprotective activity | WASHINGTON UNIVERSITY (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1330467-B1 | MODIFIED, HYDROXY-SUBSTITUTED AROMATIC STRUCTURES HAVING CYTOPROTECTIVE ACTIVITY | UNIV WASHINGTON (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060270845-A1 | 16-Hydroxyestratrienes as selectively active estrogens | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-11-30 | — | — | US | disclosed |
| US-7109360-B1 | 16-hydroxyestratrienes as selectively active estrogens | SCHERING AG (DE) | 2006-09-19 | — | — | US | disclosed |
| US-20060009438-A2 | MODIFIED, HYDROXY-SUBSTITUTED AROMATIC STRUCTURES HAVING CYTOPROTECTIVE ACTIVITY | WASHINGTON UNIVERSITY (US) | 2006-01-12 | — | — | US | disclosed |
| US-20050054624-A1 | Modified, hydroxy-substituted aromatic structures having cytoprotective activity | WASHINGTON UNIVERSITY (US) | 2005-03-10 | — | — | US | disclosed |
| US-6844456-B2 | Modified, hydroxy-substituted aromatic structures having cytoprotective activity | WASHINGTON UNIVERSITY (US) | 2005-01-18 | — | — | US | disclosed |
| US-20040029847-A1 | 8Beta-substituted-11-beta-pentyl-and 11-beta-hexyl-estra-1,3,5(10)-triene derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-02-12 | — | — | US | disclosed |
| US-20030176405-A1 | 8 Beta-hydrocarbyl-substituted estratrienes for use as selective estrogens | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2003-09-18 | — | — | US | disclosed |
| US-20020103178-A1 | Modified, hydroxy-substituted aromatic structures having cytoprotective activity | WASHINGTON UNIVERSITY | 2002-08-01 | — | — | US | disclosed |
| EP-0882735-B1 | 9 Alpha-hydroxy-8 alpha-estra-1,3,5(10)-trienes and a process for their preparation | JENAPHARM GMBH (DE) | 2000-04-19 | — | — | EP | disclosed |
| EP-0882735-A1 | 9 Alpha-hydroxy-8 alpha-estra-1,3,5(10)-trienes and a process for their preparation | Jenapharm GmbH & Co. KG (DE) | 1998-12-09 | — | — | EP | disclosed |
| US-4029648-A | Process of making gona-1,3,5(10),9(11)-tetraenes | VEB JENAPHARM (DL) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270845-A1 | 16-Hydroxyestratrienes as selectively active estrogens | ESR1, ESR2, ESRRA | SHBG 7/4885STS 293/4885NR3C1 53/4885 |
| US-20080182829-A1 | 8Beta-Hydrocarbyl-Substituted Estratrienes As Selectively Active Estrogens | ESR2, ESR1, ESRRA | SHBG 10/4885STS 579/4885NR3C1 136/4885 |
| US-20020103178-A1 | Modified, hydroxy-substituted aromatic structures having cytoprotective activity | ESR2, BAD, GPX4 | SHBG 5/4885STS 656/4885NR3C1 186/4885 |
| US-20040029847-A1 | 8Beta-substituted-11-beta-pentyl-and 11-beta-hexyl-estra-1,3,5(10)-triene derivatives | GPER1, ESRRA, ESR2 | SHBG 13/4885STS 665/4885NR3C1 63/4885 |
| US-20060009438-A2 | MODIFIED, HYDROXY-SUBSTITUTED AROMATIC STRUCTURES HAVING CYTOPROTECTIVE ACTIVITY | ESR2, BAX, GPX4 | SHBG 4/4885STS 779/4885NR3C1 151/4885 |
| US-20110015165-A1 | MODIFIED, HYDROXY-SUBSTITUTED AROMATIC STRUCTURES HAVING CYTOPROTECTIVE ACTIVITY | GPX4, NR5A1, ESR2 | SHBG 11/4885STS 780/4885NR3C1 179/4885 |
| US-20050054624-A1 | Modified, hydroxy-substituted aromatic structures having cytoprotective activity | GPX4, NR5A1, ESR2 | SHBG 11/4885STS 780/4885NR3C1 179/4885 |
| US-20030176405-A1 | 8 Beta-hydrocarbyl-substituted estratrienes for use as selective estrogens | ESR2, ESRRA, ESRRB | SHBG 11/4885STS 475/4885NR3C1 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.